Anthracyclines and trastuzumab are two of the basic antineoplastic regimens that are used as (neo)adjuvant treatment for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. The gene discussed is ERBB2; the disease is breast cancer.